Antifungal Selection for the Treatment of Onychomycosis: Patient Considerations and Outcomes
Eden Axler,Shari Lipner
DOI: https://doi.org/10.2147/idr.s431526
2024-03-05
Infection and Drug Resistance
Abstract:Eden Axler, Shari R Lipner Weill Cornell Medicine, Department of Dermatology, New York, NY, 10021, USA Correspondence: Shari R Lipner, Weill Cornell Medicine, Department of Dermatology, 1305 York Avenue, New York, NY, 10021, USA, Tel +1 646-962-3376, Fax +1 646-962-0033, Email Onychomycosis, a common fungal nail infection, affects > 20% of adults over age 60 and > 50% of people over age 70. Onychomycosis may cause pain, psychosocial problems, and secondary infections, therefore meriting treatment. This review describes the range of treatment modalities, including FDA-approved systemic drugs and topical therapies. Additionally, new and emerging oral and topical therapies are discussed. We emphasize the importance of tailoring onychomycosis therapy to individual patient characteristics, comorbidities, preferences, extent of nail involvement, and fungal species, such that physicians may optimize treatment outcomes, patient satisfaction, and safety. Keywords: dermatophyte, nail infection, topical therapy, systemic treatment, fungal susceptibility, treatment guidelines Onychomycosis is a fungal nail infection caused by species that consume keratin, as well as non-dermatophyte molds and yeasts. 1 Treatment is challenging due to high recurrence rates, patient compliance, thick nail plate barrier, biofilm formation, and emerging antifungal resistance. 2 Food and Drug Administration (FDA) approved treatment options for onychomycosis include systemic and topical antifungals. 3 As well, many non-FDA-approved and newer treatments have emerged for treating this condition. Patients with onychomycosis may be apprehensive of treatment due to perceived risks and long treatment courses. Optimal treatment for individual patients is determined by considerations of efficacy, safety, comorbidities, compliance, and cost. 4 In this review we discuss current and novel treatment options for onychomycosis to assist physicians in informed treatment decisions. Onychomycosis is predominantly caused by Trichophyton rubrum , followed by Trichophyton mentagrophytes and Epidermophyton floccosum . Dermatophytes account for 90% of toenail and 50% of fingernail infections. Candida albicans represents 2% of cases, primarily in fingernails. 5 Nondermatophyte molds, including Fusarium, Aspergillus, Acremonium, Scytalidium, and Scopulariopsis brevicaulis , make up about 8% of infections. 5,6 Searches for peer-reviewed journal articles were conducted on August 8th, 2023 and January 19th, 2024 using the PubMed/MEDLINE database with the search terms "onychomycosis treatment", "itraconazole onychomycosis", "terbinafine onychomycosis", "griseofulvin onychomycosis", "fluconazole onychomycosis", "efinaconazole onychomycosis", "voriconazole onychomycosis", "posaconazole onychomycosis", "fosravuconazole onychomycosis", "amorolfine onychomycosis", "ciclopirox onychomycosis", "tavaborole onychomycosis", and "luliconazole onychomycosis". Additionally, reference lists from identified articles were examined to identify further relevant literature. A comprehensive review of over 4000 articles was conducted, with a focus on prioritizing randomized clinical trials and pivotal trials. Studies were excluded if they were not relevant, were overshadowed by more current or larger studies, or were not in English. Studies were not excluded based on the date of publication. Griseofulvin was FDA-approved in 1959, making it the first oral agent available for treating onychomycosis. 7,8 While once the agent of choice, its use declined due to its longer treatment duration, lower efficacy, and higher recurrence rates compared to other oral antifungals. 9,10 Today griseofulvin is now rarely used for onychomycosis treatment. 9 Griseofulvin prevents the formation of intracellular microtubules, disrupts the mitotic spindle, and prevents fungal cell division. 7 The drug reaches the infection site through uptake by newly produced nail, necessitating continuous treatment as the nail grows out. 6 Consequently, griseofulvin is prescribed for extended durations in onychomycosis treatment, with recommended daily doses ranging from 500–1000mg for 6–9 months for fingernails and 12–18 months for toenails, aligned with average nail growth rates. 11,12 This prolonged treatment duration results in challenges related to low patient compliance. 11,12 Griseofulvin's spectrum of activity is limited to dermatophytes, and it is not effective against other species or mixed-organism infections. 6,13 In a prospective study with 122 onychomycosis patients treated with griseofulvin, mycological cure rates were 29% for toenails and 80% for fingernails, while clinical cure rates were 3% for toenails and 40% for f -Abstract Truncated-
pharmacology & pharmacy,infectious diseases